Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
J Clin Psychopharmacol ; 37(4): 452-455, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28590366

RESUMO

BACKGROUND: Users of antipsychotics (APs) have a risk of sudden cardiac death (SCD). Sudden cardiac death in such patients is thought to be largely due to drug-induced QT prolongation. It has been reported that many subjects with drug-induced torsades de pointes (TdP) have risk alleles associated with subclinical congenital long QT syndrome. METHODS: We investigated the effects of the risk alleles associated with long QT on the QT interval in patients receiving APs using 24-hour Holter electrocardiograms to take into account the circadian fluctuation of QT intervals. We investigated 8 single-nucleotide polymorphisms identified on a GWAS. RESULTS: We found that increased numbers of risk alleles at rs7188697 in NDRG4 and rs11970286 in PLN were the major predictors of an increased maximum QT interval over 24 hours in users of APs. CONCLUSIONS: It could be useful to perform a DNA-based analysis before the initiation of APs to reduce the risk of drug-induced torsades de pointes and SCD.


Assuntos
Antipsicóticos/uso terapêutico , Eletrocardiografia Ambulatorial/efeitos dos fármacos , Variação Genética/genética , Estudo de Associação Genômica Ampla/métodos , Frequência Cardíaca/genética , Esquizofrenia/genética , Adulto , Antipsicóticos/farmacologia , Eletrocardiografia Ambulatorial/tendências , Feminino , Variação Genética/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único/genética , Esquizofrenia/tratamento farmacológico , Fatores de Tempo
2.
Microbiol Immunol ; 60(8): 521-6, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27301664

RESUMO

Seborrheic dermatitis (SD) is a chronic inflammatory dermatologic condition in which erythema and itching develop on areas of the body with sebaceous glands, such as the scalp, face and chest. The inflammation is evoked directly by oleic acid, which is hydrolyzed from sebum by lipases secreted by skin microorganisms. Although the skin fungal genus, Malassezia, is thought to be the causative agent of SD, analysis of the bacterial microbiota of skin samples of patients with SD is necessary to clarify any association with Malassezia because the skin microbiota comprises diverse bacterial and fungal genera. In the present study, bacterial microbiotas were analyzed at non-lesional and lesional sites of 24 patients with SD by pyrosequencing and qPCR. Principal coordinate analysis revealed clear separation between the microbiota of non-lesional and lesional sites. Acinetobacter, Corynebacterium, Staphylococcus, Streptococcus and Propionibacterium were abundant at both sites. Propionibacterium was abundant at non-lesional sites, whereas Acinetobacter, Staphylococcus and Streptococcus predominated at lesional sites; however, the extent of Propionibacterium colonization did not differ significantly between lesional and non-lesional sites according to qPCR. Given that these abundant bacteria hydrolyze sebum, they may also contribute to SD development. To the best of our knowledge, this is the first comprehensive analysis of the bacterial microbiotas of the skin of SD patients.


Assuntos
Dermatite Seborreica/microbiologia , Metagenoma , Metagenômica , Microbiota , Pele/microbiologia , Adulto , Idoso , Biodiversidade , Feminino , Humanos , Masculino , Metagenômica/métodos , Pessoa de Meia-Idade , Análise de Sequência de DNA , Adulto Jovem
3.
Psychiatry Clin Neurosci ; 68(1): 78-82, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23992354

RESUMO

AIMS: In Europe and North America, schizophrenia patients treated with antipsychotic agents have a higher prevalence of obesity and metabolic syndrome compared with healthy individuals. In Japan, the prevalence of overweight/obesity in the general population is considerably lower than that in Europe and North America. The purpose of this study was to investigate the prevalence of underweight and overweight/obesity as well as laboratory data in Japanese inpatients with schizophrenia. METHODS: The subjects were 333 inpatients with schizophrenia and 191 age- and sex-matched healthy volunteers. Overweight/obesity was defined as body mass index (BMI) ≥ 25 kg/m(2) , standard weight was defined as BMI ≥ 18.5 to <25 kg/m(2) and underweight was defined as BMI < 18.5 kg/m(2) . RESULTS: A significant difference in the prevalence of the three BMI levels was observed between schizophrenia patients and controls (P < 0.001). The prevalence of underweight was significantly higher in schizophrenia patients than that in controls (P < 0.001). The prevalence of hypoproteinemia (P < 0.001) and of hypocholesterolemia (P < 0.001) were significantly higher in schizophrenia patients than in controls. In schizophrenia patients, the prevalence of hypotriglyceridemia was significantly higher in the underweight group than in the standard weight group (P = 0.003) and in the overweight/obesity group (P < 0.001). CONCLUSIONS: The prevalence of underweight in Japanese inpatients with schizophrenia may be higher compared with that in the general population. Therefore, the physical health of inpatients should be more carefully taken into account in clinical practice.


Assuntos
Povo Asiático/estatística & dados numéricos , Pacientes Internados/estatística & dados numéricos , Desnutrição/complicações , Desnutrição/epidemiologia , Esquizofrenia/complicações , Magreza/complicações , Magreza/epidemiologia , Adolescente , Adulto , Povo Asiático/psicologia , Índice de Massa Corporal , Estudos de Casos e Controles , Humanos , Pacientes Internados/psicologia , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Obesidade/complicações , Obesidade/epidemiologia , Sobrepeso/complicações , Sobrepeso/epidemiologia , Prevalência , Esquizofrenia/epidemiologia , Adulto Jovem
4.
Psychiatry Clin Neurosci ; 68(5): 353-6, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24405493

RESUMO

AIM: We examined the difference between the effects of olanzapine (OLZ) and risperidone (RIS) on PR and QT intervals among patients with stable schizophrenia using a cohort analysis. METHODS: Twenty-one subjects treated with OLZ were enrolled in the study. Following baseline assessments, which included PR and QT intervals, OLZ was switched to RIS for each subject. The same parameters were evaluated following the switch to RIS. RESULTS: All patients who had been treated with OLZ were successfully switched to RIS. In all patients, we observed a significant decrease in PR interval (t = 2.397, P = 0.029) and no change in either QTc or RR interval. In female patients, the QTc interval was significantly decreased (t = 3.495, P = 0.008) following the switch, while in male patients, the QTc interval did not change. No patients showed a PR interval of >200 ms or a QTc interval of >500 ms. CONCLUSION: OLZ treatment has a greater prolonging effect on PR and QT intervals compared with RIS. Careful attention may need to be paid to the cardiac conduction system in addition to QT prolongation during OLZ treatment.


Assuntos
Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Benzodiazepinas/efeitos adversos , Sistema de Condução Cardíaco/efeitos dos fármacos , Risperidona/efeitos adversos , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Benzodiazepinas/uso terapêutico , Estudos de Coortes , Eletrocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Risperidona/uso terapêutico , Caracteres Sexuais , Adulto Jovem
5.
J Clin Psychopharmacol ; 33(4): 525-7, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23775046

RESUMO

BACKGROUND: The prevalence of diabetes in patients with schizophrenia is 2- to 3-fold higher than in the general population. Glucose abnormalities were detected in 11.9% of Japanese schizophrenic patients in a recent cross-sectional study that included fasting glucose monitoring. However, detailed studies of glucose intolerance using the glucose tolerance test have been limited in Japanese patients with schizophrenia. We investigated the prevalence of abnormal glucose tolerance after glucose loading among Japanese inpatients with schizophrenia, with normal fasting glucose levels. METHOD: A total of 258 inpatients with schizophrenia participated in this study after giving their written informed consent. A 75-g oral glucose tolerance test was conducted in the morning after a 12-hour overnight fast. RESULTS: Among patients with normal fasting glucose, 81.3% had normal glucose tolerance, 17.3% had impaired glucose tolerance, and 1.3% were diagnosed with diabetes. CONCLUSIONS: This study showed that the frequency of impaired glucose tolerance in patients with schizophrenia with normal fasting glucose levels might be higher than in the general population. Careful monitoring and screening of patients with schizophrenia for abnormal glucose metabolism might therefore be necessary.


Assuntos
Intolerância à Glucose/epidemiologia , Esquizofrenia/epidemiologia , Adulto , Biomarcadores/sangue , Glicemia/análise , Distribuição de Qui-Quadrado , Jejum/sangue , Feminino , Intolerância à Glucose/sangue , Intolerância à Glucose/diagnóstico , Teste de Tolerância a Glucose , Humanos , Pacientes Internados , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prevalência , Esquizofrenia/sangue , Esquizofrenia/diagnóstico
6.
J Clin Psychopharmacol ; 33(3): 411-4, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23609388

RESUMO

9-Hydroxyrisperidone (9-OH-RIS) is an active metabolite of the antipsychotic drug risperidone (RIS). The total active moiety level, in other words the sum of the RIS and 9-OH-RIS serum levels, may be important for estimating the clinical effects of RIS treatment. However, there have been no consistent results reported regarding the relationship between cytochrome P450 (CYP) 2D6 or adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) variant alleles and 9-OH-RIS or total active moiety plasma levels. Seventy-four Japanese patients treated with RIS were examined in the present study. Steady-state plasma RIS and 9-OH-RIS were measured. The CYP2D6*5, CYP2D6*10, ABCB1 3435C>T, and ABCB1 2677G>T/A genotypes were detected. Multiple regression analysis showed that the dose-corrected plasma RIS levels were significantly correlated with the number of CYP2D6 variant alleles and ABCB1 3435C>T genotypes, whereas the 9-OH-RIS and total active moiety levels were significantly correlated with the ABCB1 3435C>T genotypes and with age. On the other hand, the ABCB1 2677G>T/A genotypes did not affect plasma RIS, 9-OH-RIS, or total active moiety levels. The ABCB1 3435C>T genetic polymorphism may predict plasma 9-OH-RIS and total active moiety levels.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Isoxazóis/farmacocinética , Pirimidinas/farmacocinética , Risperidona/farmacocinética , Esquizofrenia/tratamento farmacológico , Subfamília B de Transportador de Cassetes de Ligação de ATP , Adulto , Fatores Etários , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapêutico , Citocromo P-450 CYP2D6/genética , Feminino , Genótipo , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Palmitato de Paliperidona , Polimorfismo Genético , Análise de Regressão , Risperidona/uso terapêutico , Adulto Jovem
7.
Hum Psychopharmacol ; 28(2): 188-91, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23475497

RESUMO

OBJECTIVES: There have so far been few papers studying the metabolic syndrome (MetS) prevalence rate in Japanese patients with schizophrenia. We studied the MetS prevalence rate in Japanese controls and inpatients with schizophrenia and compared the prediction factors for the occurrence of MetS. METHODS: The subjects were 319 inpatients with schizophrenia and 154 controls. The predictive utilities of body mass index (BMI) and the individual components of MetS for MetS diagnosis were evaluated. RESULTS: The prevalence of MetS did not differ between schizophrenia and control subjects. Subjects with schizophrenia showed higher prevalences of the MetS criteria for high-density lipoprotein cholesterol (HDL) (p < 0.001) and waist circumference (WC) (p < 0.001). In subjects with schizophrenia, the predictive power was found to be highest for HDL, followed by WC, BMI, triglyceride, diastolic blood pressure (BP), systolic BP and fasting plasma glucose. However, in control subjects, the predictive power was found to be highest for triglyceride, followed by WC, systolic BP, BMI, HDL, diastolic BP and fasting plasma glucose. HDL was the component most predictive of MetS in subjects with schizophrenia treated with antipsychotics. CONCLUSION: Because, in normal clinical practice, it is difficult to obtain temporal measurements for all of the MetS criteria, measurement of HDL may be useful for predicting the MetS.


Assuntos
Antipsicóticos/efeitos adversos , Povo Asiático/etnologia , Síndrome Metabólica/induzido quimicamente , Síndrome Metabólica/etnologia , Esquizofrenia/etnologia , Adulto , HDL-Colesterol/sangue , Feminino , Humanos , Masculino , Síndrome Metabólica/sangue , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prevalência , Fatores de Risco , Esquizofrenia/sangue , Esquizofrenia/tratamento farmacológico , Circunferência da Cintura/fisiologia
8.
Hum Psychopharmacol ; 28(1): 94-6, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23161621

RESUMO

OBJECTIVES: There are few reports regarding quetiapine (QTP)-related QT prolongation. We examined the change in QT interval after switching from aripiprazole (ARP), olanzapine (OLZ), or risperidone (RIS) to QTP. METHODS: Twenty subjects treated with ARP, OLZ, or RIS were enrolled in the study. Following baseline assessments, which included QT interval and electrolytes, these three drugs were switched to QTP for each subject. The same parameters were evaluated following a switch to QTP. RESULTS: All 20 patients who had been treated with ARP, OLZ, or RIS were successfully switched to QTP. Significant increases were observed in the total mean corrected QT (QTc) interval after switching (p = 0.014). The coefficient of variation for the extent of change in QTc interval was 1.66. The mean QTc with ARP treatment was significantly increased after QTP treatment (p = 0.004). CONCLUSIONS: Quetiapine might have a greater effect on QTc interval than other second-generation antipsychotics. However, because there was a considerable variability in the extent of QTc prolongation after switch to QTP, further studies are required to clarify the effect of QTP on QTc interval.


Assuntos
Antipsicóticos/uso terapêutico , Povo Asiático , Dibenzotiazepinas/uso terapêutico , Substituição de Medicamentos , Frequência Cardíaca/efeitos dos fármacos , Esquizofrenia/tratamento farmacológico , Adulto , Antipsicóticos/farmacologia , Povo Asiático/etnologia , Dibenzotiazepinas/farmacologia , Substituição de Medicamentos/métodos , Eletrocardiografia/efeitos dos fármacos , Feminino , Frequência Cardíaca/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Fumarato de Quetiapina , Esquizofrenia/etnologia , Esquizofrenia/fisiopatologia , Adulto Jovem
9.
Hum Psychopharmacol ; 28(3): 215-9, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23553637

RESUMO

OBJECTIVE: We examined sex differences in the effect of olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), or quetiapine (QTP) on mean corrected QT (QTc) intervals among 222 patients with schizophrenia. METHODS: Subjects were patients with schizophrenia who were treated with either OLZ (n = 69), RIS (n = 60), ARP (n = 62), or QTP (n = 31). Electrocardiographic measurements were conducted, and the QT interval was corrected using Bazett's correction formula. RESULTS: The mean QTc interval of the QTP group was significantly longer than that of the RIS group (p = 0.002) or ARP group (p = 0.029). The mean QTc interval of the OLZ group was also significantly longer than that of the RIS group (p = 0.006). In female participants, the difference in the mean QTc interval among the four second-generation antipsychotic (SGA) groups was statistically significant (p = 0.002), whereas in male patients, there was no significant difference in the mean QTc interval among the four SGA groups. Post hoc analyses showed that sex differences in QTc interval were observed only in OLZ treatment group (p = 0.007). CONCLUSION: To our knowledge, this is the first study to demonstrate sex differences in the effect of four SGAs on the QTc interval.


Assuntos
Antipsicóticos/uso terapêutico , Síndrome do QT Longo/induzido quimicamente , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Idoso , Antipsicóticos/efeitos adversos , Aripiprazol , Benzodiazepinas/efeitos adversos , Benzodiazepinas/uso terapêutico , Dibenzotiazepinas/efeitos adversos , Dibenzotiazepinas/uso terapêutico , Eletrocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Piperazinas/efeitos adversos , Piperazinas/uso terapêutico , Fumarato de Quetiapina , Quinolonas/efeitos adversos , Quinolonas/uso terapêutico , Risperidona/efeitos adversos , Risperidona/uso terapêutico , Fatores Sexuais , Adulto Jovem
10.
Hum Psychopharmacol ; 27(1): 43-6, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22745940

RESUMO

OBJECTIVE: The sum of the serum levels of risperidone (RIS) and 9-hydroxyrisperidone (9-OH-RIS), which is the active moiety serum level, could be important for estimating the clinical effects of RIS. However, there have been no consistent results reported about the relationship between cytochrome P450 (CYP) 2D6*10 allele and plasma 9-OH-RIS or active moiety levels. We investigated the effect of the number of CYP2D6*10 alleles on steady-state plasma RIS, 9-OH-RIS, and active moiety levels in Japanese patients. METHODS: Steady-state plasma RIS, 9-OH-RIS, and active moiety levels were measured in 64 patients treated with an average dosage of 4.6 mg/day. RESULTS: The number of CYP2D6*10 alleles significantly affected dose-corrected plasma RIS levels (p = 0.001), and the median concentrations in ng/ml/mg were 0.94 (0 allele) vs. 1.73 (1 allele) vs. 3.05 (2 alleles). The number of CYP2D6*10 alleles did not affect plasma 9-OH-RIS or active moiety levels. CONCLUSION: The present study shows that the number of CYP2D6*10 alleles affected plasma RIS levels but not plasma 9-OH-RIS and plasma active moiety levels. Because the plasma active moiety levels can influence antipsychotic effects or side effects, the genetic screening of the CYP2D6*10 allele for RIS in Asian populations may not be clinically important.


Assuntos
Antipsicóticos/farmacocinética , Citocromo P-450 CYP2D6/genética , Risperidona/farmacocinética , Adulto , Alelos , Antipsicóticos/metabolismo , Feminino , Humanos , Isoxazóis/sangue , Japão , Masculino , Pessoa de Meia-Idade , Palmitato de Paliperidona , Transtornos Psicóticos/tratamento farmacológico , Pirimidinas/sangue , Risperidona/metabolismo , Esquizofrenia/tratamento farmacológico , Adulto Jovem
11.
Hum Psychopharmacol ; 27(1): 39-42, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22144033

RESUMO

OBJECTIVE: A dose-dependent increase in risk of sudden cardiac death for the antipsychotic drug risperidone was reported. However, few reports have so far addressed QT prolongation associated with the use of risperidone or its major active metabolite, which is also used as a separate antipsychotic drug, paliperidone. METHODS: The present study evaluated associations between risperidone metabolism and QT interval in 61 psychiatric patients who had been receiving risperidone for ≥4 weeks at an average dosage of 4.7 mg/day. Plasma risperidone and paliperidone levels were measured and electrocardiographic measurements were also obtained. RESULTS: There was no correlation between risperidone dosage and QTc or plasma risperidone levels and QTc. However, there was a significant positive correlation between plasma paliperidone levels and QTc (r = 0.361; p = 0.004). There was no correlation between age and dose-corrected plasma risperidone levels or between age and QTc. There was a significant positive correlation between age and dose-corrected plasma paliperidone levels (r = 0.290; p = 0.023). CONCLUSION: Clinically, paliperidone is considered to play a more important role in QT prolongation than risperidone.


Assuntos
Antipsicóticos/efeitos adversos , Isoxazóis/efeitos adversos , Síndrome do QT Longo/induzido quimicamente , Pirimidinas/efeitos adversos , Risperidona/efeitos adversos , Adulto , Fatores Etários , Antipsicóticos/administração & dosagem , Antipsicóticos/farmacocinética , Relação Dose-Resposta a Droga , Eletrocardiografia , Feminino , Humanos , Isoxazóis/farmacocinética , Masculino , Palmitato de Paliperidona , Pirimidinas/farmacocinética , Risperidona/administração & dosagem , Risperidona/farmacocinética , Adulto Jovem
12.
J Mater Sci Mater Med ; 23(5): 1291-7, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22391994

RESUMO

Highly soluble amorphous calcium phosphate powder (ACP) was added to the alginate gel as a buffering agent, in an attempt to enable widely controlled release while avoiding an acidification of the gel-environment. Therapeutic effects of the ACP-containing alginate gel which slowly releases a drug, simvastatin, on osteoporosis model rats were examined. A model drug, simvastatin, incorporated in the alginate gel with ACP up to 0.5%, was continuously released for a long time under the acidic condition. The release rate was controlled by the amount of ACP, serving as a buffer to suppress acidity. When the alginate solution intramuscularly injected in the rat, a soft gel was formed in the injected site. Simvastatin released from the gel containing 0.5% of ACP showed high therapeutic effect on osteoporosis rat. Thus, the present injectable long-sustained release system is expected to be a novel drug delivery controlling device.


Assuntos
Alginatos/síntese química , Fosfatos de Cálcio/administração & dosagem , Osteoporose/tratamento farmacológico , Sinvastatina/administração & dosagem , Alginatos/administração & dosagem , Alginatos/química , Animais , Soluções Tampão , Fosfatos de Cálcio/química , Catálise , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/síntese química , Preparações de Ação Retardada/química , Modelos Animais de Doenças , Composição de Medicamentos/métodos , Sistemas de Liberação de Medicamentos , Feminino , Géis/administração & dosagem , Géis/síntese química , Géis/química , Hipolipemiantes/administração & dosagem , Hipolipemiantes/química , Injeções , Osteoporose/patologia , Polimerização , Ratos , Ratos Sprague-Dawley , Sinvastatina/química
14.
J Pharmacol Sci ; 117(2): 125-8, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21897054

RESUMO

Anticancer drugs are classified as vesicant, irritant, and nonvesicant drugs on the basis of frequency of their vascular disorder. In this study, we compared the injuring effects of three typical anticancer drugs of each class on porcine aorta endothelial cells (PAECs). The concentration inducing 50% cell viability inhibition was lower in the order of vesicant, irritant, and nonvesicant drugs. These results suggest that injuring effects of anticancer drugs on PAECs may be relevant as an indicator of frequency of their vascular disorder, and that this experimental model may be useful for the study of vascular disorder.


Assuntos
Anticarcinógenos/toxicidade , Avaliação Pré-Clínica de Medicamentos/métodos , Células Endoteliais/efeitos dos fármacos , Irritantes/toxicidade , Animais , Aorta/citologia , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Suínos
15.
Psychiatry Res ; 270: 940-946, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30551347

RESUMO

Perineuronal nets comprise chondroitin sulfate moieties and their core proteins, and their neuropathological alterations have been implicated in schizophrenia. To explore the molecular mechanism of the perineuronal net impairments in schizophrenia, we measured the immunoreactivity of chondroitin sulfate moieties, major components of perineuronal nets, in three brain regions (postmortem dorsolateral prefrontal cortex, caudate nucleus, and hippocampus) of schizophrenia patients and control subjects. Immunoblotting for chondroitin 4-sulfate and chondroitin 6-sulfate moieties revealed a significant increase in intensity of a 180 kD band of chondroitin 4-sulfate immunoreactivity in the hippocampus of patients, although we detected no significant alteration in their immunoreactivities with any other molecular sizes or in other brain regions. The levels of immunoreactivity were not correlated with postmortem interval, age, or storage time. We failed to find such an increase in a similar molecular range of the chondroitin 4-sulfate immunoreactivity in the hippocampus of the rats chronically treated with haloperidol. These results suggest that the level alteration of the chondroitin 4-sulfate moiety might contribute to the perineuronal net abnormality found in patients with schizophrenia.


Assuntos
Sulfatos de Condroitina/metabolismo , Hipocampo/metabolismo , Esquizofrenia/metabolismo , Idoso , Animais , Estudos de Casos e Controles , Núcleo Caudado/metabolismo , Núcleo Caudado/patologia , Matriz Extracelular/metabolismo , Feminino , Hipocampo/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Córtex Pré-Frontal/metabolismo , Córtex Pré-Frontal/patologia , Ratos , Esquizofrenia/patologia
20.
PLoS One ; 11(3): e0149518, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26930407

RESUMO

BACKGROUND: Olanzapine (OLZ) treatment is associated with a high risk of weight gain, and may cause abnormalities in glycolipid metabolism. Therefore, the underlying mechanism of OLZ-related weight gain is needed to clarify but not yet been adequately determined. In recent years, adipocytokines such as leptin, adiponectin, and tumor necrosis factor (TNF)-α, which play important roles in energy homeostasis, have been suggested as biomarkers of weight gain. Here, we determined if baseline plasma concentrations of leptin, adiponectin, and TNF-α predict weight gain following OLZ treatment. METHODS: We recruited 31 schizophrenia outpatients (12 men and 19 women, 28.8 ± 10.2 years old) that were unmedicated or on another antipsychotic monotherapy medication. Baseline body mass index (BMI) and plasma levels of leptin, adiponectin, and TNF-α were obtained. All patients started or were switched to OLZ monotherapy for a maximum of 1 year. BMI was also obtained at the endpoint. RESULTS: Mean BMI change following OLZ treatment was 2.1 ± 2.7 kg/m2. BMI change from baseline to endpoint negatively-correlated with baseline leptin levels in female patients (r = -0.514, P = 0.024), but not male patients. Baseline adiponectin or TNF-α levels were not correlated with BMI change. CONCLUSION: Baseline plasma leptin can have an effect on subsequent weight gain following OLZ treatment in female patients with schizophrenia.


Assuntos
Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Leptina/sangue , Esquizofrenia/tratamento farmacológico , Aumento de Peso/efeitos dos fármacos , Adiponectina/sangue , Adolescente , Adulto , Antipsicóticos/efeitos adversos , Benzodiazepinas/efeitos adversos , Índice de Massa Corporal , Feminino , Humanos , Masculino , Olanzapina , Esquizofrenia/sangue , Fator de Necrose Tumoral alfa/sangue , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA